287930-77-2

Basic information

• Product Name: 2-[3-(S)-[3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl]-3-hydroxypropyl]phenyl-2-propanol
• Synonyms: (S)-α-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-Methylethyl)benzenepropanol;Montelukast (3S)-Hydroxy Propanol;Benzenepropanol, α-[3-[(1E)-2- (7-chloro-2-quinolinyl)ethenyl] phenyl]-2-(1-hydroxy-1- Methylethyl)-, (αS)-;2-[2-[3(S)-[3-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl]phenyl-2-propanol;Montelukast Sodium Impurity;EOS-61012;2-[(3S)-(2-(7-Chloro-2-quinolinyl)- ethenyl-phenyl)-3-hydroxy-propyl)] phenyl)-2-propanol
• CAS NO: 287930-77-2
• Molecular Formula: C₂₉H₂₈ClNO₂
• Molecular Weight: 457.99112
• Product Categories: Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 287930-77-2.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 636.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.244±0.06 g/cm3(Predicted)
• Vapor Pressure: 0-0Pa at 20-25℃
• Storage Temp.: Refrigerator
• PKA: 14.10±0.20(Predicted)
• CAS DataBase Reference: 2-[3-(S)-[3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl]-3-hydroxypropyl]phenyl-2-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-(S)-[3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl]-3-hydroxypropyl]phenyl-2-propanol(287930-77-2)
• EPA Substance Registry System: 2-[3-(S)-[3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl]-3-hydroxypropyl]phenyl-2-propanol(287930-77-2)

Safety Data

• Hazardous Substances Data: 287930-77-2(Hazardous Substances Data)

Usage

Uses

A montelukast impurity.

Upstream product

• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 149968-11-6 methyl 2-(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-oxopropyl)benzoate 
• 1015076-83-1 sodium 2-[3-(3-bromo-phenyl)-3-oxo-propenyl]-benzoate 
• 177747-94-3 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid 
• 119-67-5 o-carboxybenzaldehyde 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 1258428-71-5 trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 69352-05-2 2-(2-iodophenyl)propan-2-ol 
• 7073-69-0 2-(2-bromophenyl)propanol 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 88-67-5 2-Iodobenzoic acid 
• 88-65-3 2-bromobenzoic-acid 
• 149968-10-5 (E)-3-<2-(7-chloro-2-quinolinyl)ethenyl>-α-ethenylphenylmethanol 

Downstream Products

• 158966-92-8 montelukast 
• 1266620-74-9 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(hydroxy-1-methylethyl)phenyl]propyl]-sulfonyl]methyl]-cyclopropane acetic acid 
• 855473-51-7 1-(((1(R)-(3-(2(E)-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid methyl ester 
• 918972-54-0 [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-[1-(1-methyl)ethenyl]phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 1334676-80-0 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropane acetic acid methyl ester 
• 1351973-25-5 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-methoxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid 
• 1197374-11-0 (S)-1-(3-((E)-2-(7-chloroquinolin?2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl methanesulphonate 
• 1197374-09-6 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl acetate 
• 1352029-52-7 1R-{(3-[(E)-2-(7-chloroquinolin-2-yl) vinyl] phenyl)}-3-[2-(prop-1-en-2-yl) phenyl] propan-1-ol 
• 1351973-21-1 [S,E]-1-[[[1-[3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl]-3-[2-(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 1351973-22-2 [S,E]-1-[[[1-[3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl]-3-[2-(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid dicyclohexylamine salt 
• 1197374-12-1 [1-[(R)-1-(3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]-phenyl)-3-(2-isopropenylphenyl)propylsulfanylmethyl]cyclopropyl]acetic acid dicyclohexylamine salt 
• 190078-45-6 [S,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid sodium salt 
• 220927-27-5 (R,E)-(1-{1-{3-[2-(7-Chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl}cyclopropyl)acetic acid 

Relevant articles and documents

A synthesis process of montelukast sodium (by machine translation)

A synthesis process of montelukast sodium, relates to the field of drug synthesis, adopts a double hydroxy precursor of a sulfonyl derivative, and mercapto carboxylic acid compound, b cyclohexylamine in the reaction under the action of a catalyst, to obtain the ammonium salt, the quaternary ammonium salt is converted into the montelukast sodium. Compared with the direct synthesis of montelukast sodium, synthetic ammonium salt reaction not only conversion is higher, but also easy to separate, high purity, thus being beneficial to obtain high-purity of montelukast sodium. The synthesizing process of the synthetic route is simple, easy to operate, low requirements on equipment, can realize the large-scale production of montelukast sodium. (by machine translation)

An enantioselective formal synthesis of montelukast sodium

A formal synthesis of the antiasthma drug montelukast sodium is described, wherein the key chiral diol intermediate was accessed with greater convergence of the C-C bond-forming steps as compared to previous routes. Improved synthetic efficiency was achie

Identification, synthesis and characterization of impurities of Montelukast sodium

Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.